The shadow of generic competition has consistently loomed over copyright’s blockbuster drug, Sildenafil, triggering questions about the future of related medicinal investments. While early times saw impressive profits, the intellectual property end has allowed the door for discounted alternatives, likely diminishing earnings and presenting a real